The specified surveillance of romiplostim, a study of long-term use in aplastic anemia patients who are refractory to conventional therapies (all-case surveillance).

The specified surveillance of romiplostim, a study of long-term use in aplastic anemia patients who are refractory to conventional therapies (all-case surveillance). - The specified surveillance of romiplostim

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000056465

Enrollment

200

Registered

2024-12-16

Start date

2019-08-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

aplastic anemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Aplastic anemia patients who are refractory to conventional therapies.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
1.Safety (1) Bleeding (2) Thromboembolism (3) Myelofibrosis (4) Hematologic malignancies 2.Efficacy (1) Change in platelets (2) Change in Hb levels (3) Change in neutrophils	—

Countries

Japan

Contacts

Public ContactHiroshi Kuwazawa

Kyowa Kirin Co.,Ltd. Pharmacovigilance division

hiroshi.kuwazawa.wd@kyowakirin.com03-5205-7200

Outcome results